Clinical Trial Update: Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the addition of ivosidenib to chemotherapy for IDH1-mutant relapsed or refractory acute myeloid leukemia, including recurrent or refrac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• Ivosidenib (ivosidenib)

Snippet

Sponsor: Northwestern University | Conditions: Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Status: ACTIVE_NOT_RECRUITING